A Novel Multi-Component Formulation Reduces Inflammation In Vitro and Clinically Lessens the Symptoms of Chronic Eczematous Skin
Name
ijms-24-12979.pdf
Size
5.7 MB
Format
Adobe PDF
Checksum (MD5)
7110bbfa1db63159d6c2c46ca7b6299a
Author(s)
Kim, Jihee
Jung, Eunjoong
Yang, Wonmi
Kim, Chun-Kang
Durnaoglu, Serpen
Oh, In-Rok
Kim, Chan-Wha
Sinskey, Anthony J.
Mihm, Martin C.
Lee, Ju Hee
Date Issued
August 19, 2023
Publisher
Multidisciplinary Digital Publishing Institute
Citation
International Journal of Molecular Sciences 24 (16): 12979 (2023)
Version
Final published version
Abstract
Long-term treatments for inflammatory skin diseases like atopic dermatitis or eczema can cause adverse effects. Super Protein Multifunction (SPM) was investigated as a potential treatment for managing skin inflammation by monitoring the expression of pro-inflammatory cytokines induced using LPS and poly(I:C)/TNFα in HaCaT keratinocytes and Hs27 fibroblasts as measured via RT-PCR. SPM solution was also assessed for its effect on cytokine release, measured using ELISA, in a UVB-irradiated 3D human skin model. To evaluate the efficiency of SPM, 20 patients with mild eczematous skin were randomized to receive SPM or vehicle twice a day for three weeks in a double-blind controlled trial. In vitro studies showed SPM inhibited inflammation-induced IL-1β, IL-6, IL-33, IL-1α, TSLP, and TNFα expression or release. In the clinical study, the SPM group showed significant improvements in the IGA, PA, and DLQI scores compared to the vehicle group. Neither group showed significant differences in VAS (pruritus). Histological analysis showed reduced stratum corneum thickness and inflammatory cell infiltration. The results suggest that SPM may reduce inflammation in individuals with chronic eczematous skin.
MIT Department
Massachusetts Institute of Technology. Department of Biology
Terms of Use
Creative Commons Attribution 4.0 International License
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.3390/ijms241612979
